Renal cell carcinoma represents 2-3% of all cancers and is the most frequent solid lesion of the kidney. incidental diagnosis through imaging studies is approximately 50%, and the majority of those cases are asymptomatic. Management is based on radical surgical treatment and postoperative follow-up through imaging techniques is essential for detecting local or systemic recurrence. A 60-year-old man had a past history of left radical nephrectomy due to renal tumor 10 years earlier. Clinical manifestation was painless, gross hematuria. CT-urography revealed right ureteropelvic ectasia with a lesion occupying the distal third of the ureter that produced a negative filling defect. Endoscopic revision, lesion excision, and adjuvant treatment based on the tyrosine kinase inhibitor, sorafenib, were carried out. This clinical case underlines the importance of strict follow-up in patients with renal tumors since there is no clear knowledge as to the metastatic behavior and predictable tumor dissemination routes in renal cell carcinoma. 
Paciente masculino de 60 años de edad, con antecedente de nefrectomía radical izquierda 10
Introduction
Renal cell carcinoma (RCC) has the capacity to metastasize to multiple organs. The most common sites include the lung, lymph nodes, bone, and liver. Metastasis in abdominopelvic organs is uncommon and it is identified through necessary radiographic support.
Other infrequent metastatic sites of RCC have been reported (table 1) , underlining its unclear manner of dissemination. Pelvic organ metastasis is generally secondary to RCCs originating on the left side, supporting the idea of the venous route as the dissemination pathway.
1-5

Case presentation
A 60-year-old man came to the emergency department with symptoms of painless gross hematuria with no clotting. Anamnesis revealed that he underwent left radical nephrectomy due to a kidney tumor and the histopathology study reported a 9 cm tumor with central necrosis that invaded the renal capsule. The patient did not go to the follow-up appointments after his surgery. Physical examination identified the abdominal scar from the left lumbotomy. There were no signs of visceromegaly or painful points. The laboratory work-up reported: hemoglobin 16 g/ dl, platelets 167,000, creatinine 1 mg/dl, TB 1.65mg/dl, DB 0.5 mg/dl, iB 1.07mg/dl, and alkaline phosphatase 134 U/l. non-contrast and contrast-enhanced tomography scans revealed the surgical absence of the left kidney, right ureteropelvic ectasia with a rounded lesion, 2 x 2 cm in diameter, occupying the right ureter at the level of the iliac vessel intersection. it had a density of 10-20 HU and was enhanced to 50-60 HU in the contrasted phase (figs. 1 and 2). Given the tomographic evidence of the tumor lesion, ureteroscopy, biopsy, and tumor resection were performed ( fig. 3 ).
Histopathology report: clear cell carcinoma, dysplastic epithelium, and fibrosis ( fig. 4 ). immunohistochemistry study was positive for CD10 and vimentin. There was little Ureteroscopy: hypervascularized, hyperemic, and rounded right ureteral tumor.
Immunohistochemical study for vimentin (x20). Intense, diffuse cytoplasmic positivity is observed (black arrow). The urothelium to the right of the image does not express vimentin (white arrow). clinical manifestation is recurrent gross hematuria. The mechanism of metastatic dissemination is unknown. However, endoluminal, hematic, and lymphatic dissemination are postulated. 10 immunohistochemical analysis of metastases essentially consists of studying the presence of intermediate filaments of cytokeratin in the tumor cells.
When renal tumors present with unusual morphologies or distinct histologic patterns, the immunohistochemical stains are of the utmost importance for the differential diagnosis.
An a mesenchymal marker, vimentin is expressed in the majority of types (87 to 100%) of conventional and papillary clear cell renal cell carcinoma. 11 expression for p63 in the cytokeratin profile, ruling out an epithelial origin of the lesion (figs. 5 and 6).
Based on the histopathologic and immunohistochemistry results, the decision was made to initiate adjuvant therapy with oral sorafenib 400 mg every 12 h for 2 months. The patient had favorable therapeutic progression with no tomographic evidence of tumor recurrence.
Discussion
RCC can extend into the renal pelvis and ipsilateral ureter, [6] [7] but there are few reports of metastasis to the contralateral ureter after radical nephrectomy. [8] [9] The most common CD 10 can be useful in diagnosing RCC, but it does not confirm the diagnosis, given that CD 10 is present in multiple neoplasias. 12 The marker p63 is expressed in high percentages of urothelial neoplasias, but it is not expressed in renal cell carcinoma, therefore it is useful in the differential diagnosis of neoplasias of epithelial origin. 13 Metastatic RCC resection through ureterectomy, radical nephrectomy, or the conservative endourologic technique improves long-term survival in 59 and 31% at 3 and 5 years, respectively.
14-15 Our patient underwent endourologic resection to avoid the need for later dialysis that would increase morbidity and mortality.
Sorafenib is a potent inhibitor of kinases and the VEGF in vitro and has a great cytostatic capacity. We administered it to our patient with good clinical response and subsequent radiographic results.
Conclusions
Given the unpredictable metastatic dissemination of RCC, strict postoperative clinical and radiographic follow-up is of the utmost importance in the search for surgical site metastasis, distant metastasis, and metastasis to the rest of the urinary system. When there is evidence of tumor recurrence, immunohistochemistry studies are essential for correct diagnosis and management.
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